A recent study suggests that patients who come off new weight-loss injections like Wegovy and Mounjaro tend to recover reduced body mass far faster than those who stop conventional lifestyle regimens.
Findings released in a leading health publication demonstrates that while overweight individuals can lose about a fifth of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"Individuals using these drugs must be informed of the risk of quick rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.
Such speed of recovery means a return to pre-treatment weight within about a year and a half.
Comparing Approaches
The analysis, which reviewed dozens of trials involving thousands of participants, compared the outcomes of these new drugs with older methods.
Researchers note that people who lose weight through dieting generally see a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
Understanding the Fast Regain
Doctors believe the mechanism of the jabs explains the amplified regain.
The injections imitate a body's own chemical called GLP-1, which controls appetite.
"Artificially providing GLP-1 concentrations far above than normal could lead to the system to generate a reduced amount of its own natural hormone, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this medication leads to hunger is unsuppressed, making binge eating a significant risk."
A Chronic Condition?
The NHS advise the injections for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
Professionals contend that, considering the likelihood of weight regain, the therapy should be considered long-term.
This perspective is reinforced by pharmaceutical companies, who say that the results "highlight the long-term nature of obesity," akin to managing diseases like diabetes.
User Testimonies
People who have discontinued the medication explain a powerful return of cravings.
"I experienced a switch that goes on and you become extremely hungry," said a patient.
This difficulty is compounded if individuals have not developed lasting lifestyle or habit changes during treatment.
Widespread Use
Figures suggest that a significant number of people in the UK have tried these injections in the past year, with demand remaining high.
- Adoption is higher among women compared to males.
- The middle-aged age group shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, researchers caution that while these medications are powerful agents for shedding pounds, they are not a permanent cure and lasting health benefits likely depends on integrated behavioural support.
